Propel Bio Management’s Cabaletta Bio CABA Stock Holding History

Propel Bio Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.93M	Buy	+2,049,471	New	+$5.78M	2.09%	16

Other funds holding CABA

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Propel Bio Management's CABA Position: Q3 2026 in Review

Propel Bio Management opened a new position in Cabaletta Bio (CABA) in Q3 2026: 2,049,471 shares worth $3.93M. The stake represents 2.09% of the portfolio and ranks #16 among its holdings.

86 funds tracked by Wall St. Rank hold CABA as of Q3 2026.

Propel Bio Management held 2,049,471 shares of Cabaletta Bio worth $3.93M as of Q3 2026.
Cabaletta Bio was a new Propel Bio Management position in Q3 2026.
Cabaletta Bio made up 2.09% of Propel Bio Management's portfolio in Q3 2026, its #16 holding.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2026.

Based on Propel Bio Management's 13F filing for Q3 2026, filed 13 Nov 2026.